Measurement of health-related quality-of-life (HRQOL) in patients with breast cancer, and in cancer patients in general, has been a major research focus over the past quarter century. This interest in HRQOL is reflected in the development and validation of HRQOL instruments by groups in both North America (1) and Europe (2), and by the almost routine inclusion of HRQOL measurement in clinical trials of breast cancer patients. The HRQOL data are intended to help guide clinical decision making regarding selection of optimal treatment, to provide information about the experience of patients receiving treatment and, potentially, to predict prognosis. The first of these goals is best addressed in the context of randomized clinical trials, whereas the latter two goals can often be addressed by using a variety of observational and interventional study designs.
Measurement of health-related quality-of-life (HRQOL) in randomized clinical trials in breast cancer has become common. In this review, we take stock of the contribution that HRQOL measurement in breast cancer clinical trials makes to clinical decision making regarding selection of optimal treatment. A series of MEDLINE searches was conducted to identify all randomized trials in breast cancer that included self-reported HRQOL or psychosocial outcomes. A total of 256 citations were identified that included HRQOL or psychosocial outcomes in breast cancer patients, and 66 of these involved randomized clinical trials of treatment. These 66 reports of breast cancer clinical trials of treatment are discussed in this review. Forty-six of the trials evaluated biomedical interventions, and 20 evaluated psychosocial interventions. Among the biomedical trials, eight trials evaluated HRQOL in primary management of breast cancer, seven trials evaluated HRQOL in adjuvant therapy of breast cancer patients, 20 trials involved metastatic breast cancer, eight trials involved symptom control/supportive care, and three trials evaluated different approaches to investigation or follow-up of breast cancer patients. Among the psychosocial trials, 13 trials evaluated HRQOL in adjuvant therapy of breast cancer patients, and their partners or spouses, six trials involved metastatic breast cancer, and one trial focused on symptom control. We found that the contribution of HRQOL measurement to clinical decision making depended on the clinical setting. In primary management of breast cancer, where medical outcomes of several treatment options are equivalent, HRQOL measurement provided added information for clinical decision making beyond that of traditional medical outcomes. In trials in the adjuvant setting, HRQOL measurement did not influence clinical decision making. In metastatic disease, HRQOL outcomes provided little information beyond that obtained from traditional medical outcomes, including toxicity. In the symptom control/supportive care setting, results of HRQOL questionnaires targeting specific symptoms (e.g., emesis) guided treatment decisions. In psychosocial intervention trials, psychosocial and/or HRQOL measurements often provided the only outcome information; therefore, selection of instruments that captured attributes likely to be altered by the intervention was essential. Until results of ongoing trials in breast cancer are available, caution is recommended in initiating new HRQOL studies unless treatment equivalency is expected, or unless the HRQOL questions target unique or specific issues that can only be addressed through patient self-report, including outcomes of psychosocial interventions. [ Measurement of health-related quality-of-life (HRQOL) in patients with breast cancer, and in cancer patients in general, has been a major research focus over the past quarter century. This interest in HRQOL is reflected in the development and validation of HRQOL instruments by groups in both North America (1) and Europe (2) , and by the almost routine inclusion of HRQOL measurement in clinical trials of breast cancer patients. The HRQOL data are intended to help guide clinical decision making regarding selection of optimal treatment, to provide information about the experience of patients receiving treatment and, potentially, to predict prognosis. The first of these goals is best addressed in the context of randomized clinical trials, whereas the latter two goals can often be addressed by using a variety of observational and interventional study designs.
Measurement of HRQOL in randomized clinical trials increases burden on study participants, enhances trial complexity, and is time-consuming and expensive. Although there is a general consensus that HRQOL measurements increase the comprehensiveness of clinical trial outcomes and enhance understanding of treatment effects, the extent to which currently available HRQOL instruments provide information beyond that obtained with other outcome measures (e.g., tumor recurrence or response, survival, toxicity, and performance status) is not clear. Nor is it clear whether HRQOL measurements influence clinical decision making or whether the contribution of HRQOL measurement to clinical decision making varies according to stage of disease or type of intervention (i.e., biomedical or psychosocial).
The latter distinction is particularly important to planners of clinical trials-that is, if HRQOL measurement is of greater value in patients with particular stages of disease than in others, or in some clinical settings than in others, then efforts (and resources) can be shifted to those settings. In this review, we examine the contribution of HRQOL measurement to treatment selection in a variety of clinical settings, and we attempt to identify those settings in which HRQOL measurement is likely to have the greatest impact on selection of optimal treatments. Potential factors contributing to this assessment include equivalency (or nonequivalency) of the treatments being compared, the goals of treatment (prolongation of survival versus palliation), the severity of disease symptoms and treatment toxicity, and the outcomes (i.e., medical versus psychosocial) that are likely to be influenced by the treatment(s) being studied.
This review arises out of activities of the Cancer Outcomes Measurement Working Group of the National Cancer Institute (NCI), which is examining a broad range of HRQOL research in a spectrum of commonly occurring cancers. Many of the group's activities will be reported elsewhere. Here we focus on a specific issue-the contribution of HRQOL measurements in breast cancer clinical trials to the selection of optimal treatment in various clinical settings. Specifically, in this review, we take stock of what has already been learned from HRQOL measurement in clinical trials in breast cancer patients, focusing on the impact of these measurements on clinical decision making regarding selection of optimal treatments over and above the impact of more traditional medical outcomes (e.g., response, survival, and toxicity). We define HRQOL measurement as the self-report of the impact of breast cancer and its treatment on some aspect of function (e.g., physical, role, emotional, or social). Consequently, measurement of self-reported symptoms only (e.g., pain and nausea) or recording of toxicity only was not considered an HRQOL measurement. The decision to exclude studies that recorded self-reported symptoms and/or toxicity only was made to facilitate identification of the impact of the more recently developed HRQOL measurement approaches on treatment selection. It was not intended to minimize the importance of the measurement of symptoms and/or toxicity in breast cancer patients. Nor was our focus on the contribution of HRQOL measurement to treatment selection intended to undermine the importance of HRQOL measurement in describing the experience of cancer patients or in predicting prognosis.
Purpose of the Review
Our objectives were to 1) assemble the literature on HRQOL measurement in randomized clinical trials in breast cancer, including all HRQOL instruments meeting the above definition; 2) identify the most frequently used HRQOL measurement instruments; 3) describe HRQOL measurement in breast cancer clinical trials with respect to time trends (Table 1) , phase of disease and its treatment, and types of intervention studied; 4) determine the incremental contribution of HRQOL measurement to clinical decision making beyond that of traditional medical outcomes (including toxicity); and 5) identify areas for future research involving HRQOL measurement in clinical trials in breast cancer.
Search Methods
A series of computerized MEDLINE database searches were conducted in May and June of 2001 using the following unrestricted search strategies: breast cancer and [1] QOL, [2] QOL and instruments, [3] Hospital Anxiety and Depression Scale (HADS), [4] Cancer Rehabilitation Scale (CARES), [5] Functional Living Index for Cancer (FLIC), [6] European Organisation for Research and Treatment of Cancer QOL Questionnaire C-30 (EORTC QLQ-C30), [7] Functional Assessment of Cancer Therapy (FACT), [8] Breast Cancer Chemotherapy Questionnaire (BCQ), [9] Profile of Mood States (POMS), [10] Medical Outcomes Study Short Form 36 (MOS-SF-36), [11] Symptom Distress Scale (SDS), [12] Rotterdam Symptom Checklist (RSCL), [13] State Trait Anxiety Index (STAI), [14] QOL and randomized trials, and [15] QOL and clinical trials. These searches were supplemented by more focused MEDLINE searches to identify companion publications (e.g., follow-up articles and reporting of medical outcomes) and to further explore areas in which few articles were identified (e.g., adjuvant therapy). MEDLINE searches were supplemented by reviews of authors' files and discussions with leading experts to identify additional trials that had not been identified in the computerized literature searches described above. For the purposes of this review, we used articles meeting the following criteria: 1) full reports published in English after 1975; 2) randomized clinical trials of breast cancer treatment (not prevention), including surgery, chemotherapy, hormone therapy, supportive care, or psy- Table 1 . Distribution of randomized clinical trials for breast cancer treatment by publication year, type of intervention (i.e., biomedical and psychosocial), and phase of illness and its treatment* 1980-1984 1985-1989 1990-1994 1995-1999 2000-2001 †  Total   Biomedical intervention  Primary management  0  3  2  2  1  8  Adjuvant setting  0  0  0  5  2  7  Metastatic disease  0  2  3  9  6  20  Follow-up  0  0  2  1  0  3  Symptom control  0  0  5  2  1  8  Subtotal  0  5  12  19  10  46 Psychosocial intervention ‡  Adjuvant setting  1  1  0  6  5  13  Metastatic disease  1  0  1  2  2  6  Symptom control  0  0  0  0  1  1  Subtotal  2  1  1  8  8  20  Total  2  6  13  27  18 ‡There were no psychosocial intervention trials focused exclusively on the "primary management" or "follow-up" settings. chosocial intervention; 3) documentation of HRQOL outcomes (trials that measured utilities only were excluded because of the single-item nature of utility measurement); 4) use of a patient self-report measure that examined general HRQOL, cancerspecific or breast cancer-specific HRQOL, or psychosocial variables. Both unidimensional and multidimensional HRQOL instruments were acceptable; however, measurement strategies that examined single symptoms only (e.g., pain or nausea) were excluded. Titles and abstracts of 2183 citations were identified from the MEDLINE searches. After duplicate citations and publications that did not report QOL data were eliminated, a total of 256 citations were identified that included HRQOL outcomes in breast cancer patients. Some of these reports addressed validation of HRQOL instruments, whereas others reported results of cross-sectional or observational studies. The latter were excluded from this review. A total of 66 citations that involved randomized clinical trials of treatment in breast cancer and that included self-reported HRQOL outcomes form the basis for this review.
RESULTS OF THE LITERATURE SEARCH
The results of the literature search for citations meeting the above criteria are summarized in Table 1 , which classifies reports by type of intervention, phase of the illness and its treatment, and year of publication (within a 5-year range). More than two-thirds of the reports (46 of 66) assessed biomedical interventions; approximately 40% of those (20 of 46) were conducted in patients with metastatic disease. Of the psychosocial interventions, 60% (12 of 20) were conducted in the adjuvant setting. The rate of publication of studies reporting HRQOL outcomes has increased in recent years, with approximately 70% (45 of 66) of the publications appearing since 1995. Given the time lag between study design and reporting, it is likely that there are a large number of ongoing studies whose results have yet to be reported.
The most commonly used HRQOL instruments are shown in Table 2 (other HRQOL instruments are listed in Tables 3-7) . The instruments used in the biomedical intervention trials differed somewhat from those used in the psychosocial intervention trials. In the biomedical intervention trials, the EORTC QLQ-C30 (2-5) and the RSCL (10, 11) , two cancer-specific HRQOL measures, were the most commonly used instruments. In the psychosocial intervention trials, the POMS (8), a measure of mood, was the most commonly used instrument, followed by the CARES and the MOS-SF-36 (9) . Approximately 70% of the studies (46 of 66) used at least one of the nine most common (i.e., used in more than one study), well described, and validated HRQOL instruments listed in this table. Seventeen of the biomedical intervention trials used none of these instrumentssome used other validated instruments designed specifically for the trial in question (this was most common in studies of primary management, symptom control, and metastatic disease); however, some used novel instruments with little documentation of validation (Tables 3-7) , making interpretation and cross-study comparison of results difficult. The use of novel or unvalidated HRQOL instruments was less common in psychosocial intervention trials; none of these studies used such instruments as the only outcome measure.
Ideally, HRQOL instruments that are used in clinical trials should be sensitive (i.e., responsive) to change over time (15) . That is, HRQOL instruments that distinguish among groups of patients or that predict outcomes but that do not respond in a meaningful way to changes in underlying HRQOL are of little benefit in the clinical trial setting. Thus, instruments that measure state rather than trait characteristics and instruments that have scaling options that are sufficiently fine to allow for identification of improvement or deterioration in the attribute(s) being measured by the instrument are most likely to be useful in clinical trials. The nine HRQOL instruments shown in Table 2 have all been shown to be sensitive to changes in HRQOL in at least one clinical setting, although not all factors or subscales †Some studies used more than one HRQOL instrument. ‡"Other" means that a variety of less common, sometimes unvalidated HRQOL instruments were used in these randomized clinical trials.
responded in a similar fashion. Furthermore, the ability of these instruments to detect small but clinically important changes is not clear. When sensitivity to clinically important change is not documented and when statistically significant effects of treatments on HRQOL are not identified, failure to detect effects of interventions on HRQOL must be interpreted with caution.
SUMMARY OF THE EVIDENCE
Details of the 66 randomized trials, including information on the key methodologic characteristics of each trial, are provided in Tables 3-7 . Trial sample size refers to the total number of eligible patients in each study. HRQOL sample size is defined, when possible, as the number of patients who completed at least one HRQOL assessment, preferably the baseline assessment. At times, HRQOL sample size was derived from tables and figures (i.e., maximum number of respondents). With respect to missing data, any mention of the extent of missing data, even if limited to overall compliance, was classified as having adhered to the methodologic characteristic. Information on missing data was superficial for most trials and will be reviewed in detail in the No *BCQ ‫ס‬ Breast Cancer Chemotherapy Questionnaire; BCS ‫ס‬ breast-conserving surgery; BSI ‫ס‬ Brief Symptom Inventory; HADS ‫ס‬ Hospital Anxiety and Depression Scale; HRQOL ‫ס‬ health-related quality of life; LASA Scales ‫ס‬ Linear Analog Self-Assessment Scales; MRM ‫ס‬ modified radical mastectomy; NCI ‫ס‬ National Cancer Institute; OR ‫ס‬ odds ratio; POMS ‫ס‬ Profile of Mood States; RSCL ‫ס‬ Rotterdam Symptom Checklist; S/S ‫ס‬ sample size; STAI ‫ס‬ State-Trait Anxiety Inventory; XRT ‫ס‬ radiation treatment; -‫ס‬ not stated.
†For "Missing data," "Statistical methods," and "Timing of HRQOL assessment," "Yes" means that the methodologic characteristic described in the text was satisfied and "No" means that the methodologic characteristic was not satisfied.
‡When only HRQOL outcomes (and not medical outcomes) were reported, "Yes" was entered. §Validated questionnaire. †For "Missing data," "Statistical methods," and "Timing of HRQOL assessment," "Yes" means that the methodologic characteristic described in the text was satisfied and "No" means that the methodologic characteristic was not satisfied.
‡When only HRQOL outcomes (and not medical outcomes) were reported, "Yes" was entered. §Validated questionnaire. (Table continues) following sections. Adequate reporting of timing of HRQOL assessments required that the trial report the precise pre-trial definition of the time intervals between HRQOL evaluations. Any report of the statistical methods used to analyze HRQOL data was classified as having adhered to the methodologic characteristic. In most studies, HRQOL outcome was a secondary end point, and precise methods for data collection and quality control were rarely stated. These methodologic standards were applied independently by two of the authors (P. J. Goodwin, L. J. Bordeleau); disagreements were resolved by discussion. Tables 3-7 also include a brief description of the intervention(s) studied, the HRQOL instruments used, the medical and HRQOL outcomes as reported by the investigators, and an assessment of whether the information obtained from HRQOL measurement in the trial influenced clinical decision making regarding the use of the intervention under investigation. In this review, we have not performed a quantitative meta-analysis; instead, we have focused on the extent to which the measurement of HRQOL contributed qualitatively to clinical decision making (i.e., to selection of the optimal treatment among those treatments being studied) in this group of randomized clinical trials.
Primary Management: Surgery, Radiation Therapy, Hormone Therapy
Eight randomized clinical trials evaluated HRQOL in the primary management of breast cancer (Table 3) . Five (16) (17) (18) (19) (20) (21) of these studies compared mastectomy with breast-conserving surgery (BCS) plus radiation treatment (XRT). All but three (19, 20, 23) of the eight studies provided information on overall rate of missing HRQOL questionnaires. The rate of missing items (21) and the reasons for missing data (16) were provided in one study each. The five studies that compared mastectomy with BCS plus XRT used a variety of psychosocial questionnaires. Two of these studies also included medical outcomes (20, 21) ; neither identified a statistically significant difference in recurrence or survival rates, in keeping with other published studies (25) . Four studies (17, 18, 20, 21) identified at least one aspect of body image (including emotional reaction to, or satisfaction with, body image) that was better in women undergoing BCS plus XRT than in women undergoing mastectomy. One study (20) reported an improvement in sexual activity among older (but not younger) women receiving BCS plus XRT, whereas another study (21) reported that women who underwent BCS plus XRT were more satisfied with their treatment than women who underwent mastectomy. One study (18) identified a range of psychological reactions (i.e., feelings and concerns) that were better in women undergoing BCS plus XRT than in women undergoing mastectomy, but this study did not use a wellvalidated HRQOL instrument to measure these reactions.
The equivalence of BCS combined with radiation to mastectomy with respect to distant recurrence and survival is now widely accepted (25) . Although it may seem obvious that, in terms of HRQOL, BCS would be the preferred treatment option over mastectomy, demonstration of enhanced satisfaction with body image, of enhanced sexual functioning, and of enhanced psychological status after BCS provides an empiric foundation for this conclusion (17, 18, 20, 21) . However, the finding that not all aspects of HRQOL were better in patients undergoing BCS, coupled with a failure of these studies to identify overall differences in HRQOL, suggests that, for individual women, mastectomy may remain a reasonable alternative. Although some nonrandomized studies have suggested an increased fear of recurrence after BCS, reduction in this fear after BCS was documented in one of the randomized trials (18) studied here.
The remaining three studies (22) (23) (24) that evaluated HRQOL in the primary management of breast cancer included a report comparing BCS with and without radiation (22) , which demon- †For "Missing data," "Statistical methods," and "Timing of HRQOL assessment," "Yes" means that the methodologic characteristic described in the text was satisfied and "No" means that the methodologic characteristic was not satisfied.
‡When only HRQOL outcomes (and not medical outcomes) were reported, "Yes" was entered. "Yes/No" was entered when it was not clear whether HRQOL influenced clinical decisions. §Validated questionnaire. HRQOL data available in 49 patients; only 35 patients were included in the analysis. ¶Of the 294 eligible patients, 180 completed baseline HRQOL questionnaires. No (Table continues) strated a transient worsening in HRQOL during radiation treatment. Nevertheless, radiation reduced local recurrence without influencing overall survival (OS), and the authors of the study recommended that radiation be used. Another report (23) examined different radiation dose and fractionation schedules without reporting medical outcomes. The higher dose regimen (i.e., 50 gray (Gy)/25 fractions) was associated with more weight gain, disruption of private life, and a less positive outlook on life at the completion of treatment than the lower dose regimen (i.e., 40 Gy/15 fractions), but no differences in these HRQOL measures were present 6 months later. A final study (24) examined the role of surgery in elderly women receiving tamoxifen for primary breast cancer. Although local control was better when surgery was used than when surgery was not used, no differences in HRQOL were seen. In summary, in studies of primary management of breast cancer, HRQOL measurement provided information that was useful in selecting optimal treatment when two medical treatments were demonstrated to have equivalent medical outcomes; that is, demonstration of enhanced HRQOL (particularly body image) with BCS and with lower dose radiation can help guide treatment recommendations.
Adjuvant Therapy: Chemotherapy, Hormone Therapy
A surprisingly small number of published studies (n ‫ס‬ 7) of adjuvant therapy of breast cancer patients have included HRQOL outcomes (Table 4 ). There are likely to be additional ongoing adjuvant studies that have measured HRQOL outcomes that have not yet been published because recurrence and survival data are not mature. It is also possible that HRQOL outcomes in some trials were not reported for those trials in which enhanced survival in one treatment arm led to treatment recommendations. Two of the published studies (27, 29) reviewed here used the BCQ, two (28, 30) Table 4 , HRQOL measurements were often performed on a subset of patients. All but one study (26, (28) (29) (30) (31) provided information on the overall rate of missing HRQOL questionnaires (none provided information on missing questionnaire items); the remaining study (27) limited the analysis of HRQOL to complete cases. Reasons for missing data were addressed in three studies (29) (30) (31) . All studies reported methods of statistical analysis, and all but one (28) reported timing of HRQOL assessment.
In general, use of chemotherapy, especially more aggressive chemotherapy, was associated with worse HRQOL than was seen with hormonal interventions or less aggressive chemotherapy. However, the effects on HRQOL were often transient, occurring during treatment but resolving after treatment was completed (26, 27, 29) . In a trial of goserelin and tamoxifen (31) , some aspects of HRQOL were found to be worse with goserelin, others to be worse with tamoxifen, and some to be similar regardless of treatment. Two reports (29, 30) evaluated HRQOL using more than one instrument or approach to analysis. One report (29) found that use of the BCQ versus the quality-adjusted time without symptoms (q-TWIST) instrument, essentially a utility-based measurement, yielded HRQOL effects that were in opposite directions. In the other report (30) , a detailed analysis found that the HRQOL effects depended on the statistical approach used, with no differences in HRQOL between the treatments being seen when area under the curve or time-tominimum or time-to-maximum scores were used, but enhanced HRQOL for one treatment when mean, median, and minimum summary measures were used. These thoughtful analyses highlight the need for research to understand the meaning of results obtained using different HRQOL instruments and to evaluate different approaches to statistical analysis. These issues have been explored extensively in Statistics in Medicine (32) .
Because the ultimate goal of adjuvant treatment is to improve long-term survival, short-term toxicity is often accepted. Only if †For "Missing data," "Statistical methods," and "Timing of HRQOL assessment," "Yes" means that the methodologic characteristic described in the text was satisfied and "No" ‫ס‬ means that the methodologic characteristic was not satisfied.
‡When only HRQOL outcomes (and not medical outcomes) were reported, "Yes" was entered. §Validated questionnaire.
Overall S/S ‫ס‬ 57; complete results in 37 patients. No difference in survival.
Yes (Table continues) adjuvant treatments are shown to have equivalent effects on recurrence and survival is it likely that transient HRQOL effects will influence treatment decisions. It can be seen from Table 4 that this was the case for the trials reviewed here. In general, HRQOL effects were either absent, transient, or associated with observed toxicity. In only one study (31) did HRQOL data provide potentially important information that was not available using traditional medical outcomes. The Physical Symptoms and Problem List used in the trial of goserelin and tamoxifen identified greater toxicity with goserelin (31). This questionnaire was more focused on symptoms and less on functioning than most HRQOL instruments, and it is arguable that much of the information obtained from it could have been obtained by collecting toxicity data. Furthermore, if the longer time to first cancer event in women receiving goserelin persists with longer follow-up, these HRQOL results, which indicate greater toxicity with goserelin, will probably not play an important role in treatment decisions, and goserelin will be recommended as the optimal treatment. In summary, in the adjuvant setting, where the goal of treatment is to delay recurrence and/or prolong survival, information obtained using HRQOL measures has had little impact on clinical decision making. It is possible that long-term HRQOL assessments addressing potential late toxicities (e.g., cognitive functioning, menopause) or results of completed and/or ongoing studies that have yet to be reported may provide a different perspective on the contribution of HRQOL measurement to selection of optimal treatment in the adjuvant setting. This question should be explored in future research (33) .
Metastatic Disease: Chemotherapy, Hormone Therapy
The metastatic setting has given rise to the largest single group of HRQOL trials in breast cancer (Table 5 ). We examined 20 such trials. Measurement of HRQOL in these studies was at times limited to a small number of items. A range of HRQOL instruments was used in these studies, the most common being the EORTC QLQ-C30 and the RSCL. Six trials (34, 35, 37, 38, 40, 43) used instruments that were relatively uncommon or that had been modified specifically for the study; some evidence of validity was available for most of these instruments. Thirteen studies (34, 36, 37, (41) (42) (43) (44) (46) (47) (48) (49) (50) (51) provided information on the overall rate of missing HRQOL questionnaires. The rate of missing items was reported in two studies (41, 49) , and reasons for missing data were provided in eight (36, 37, 42, 44, (47) (48) (49) (50) . Missing data were often substantial, leading to concern about poor generalizability and bias in HRQOL results (32) . Most of these studies provided information on statistical methods of analysis and on timing of HRQOL measurements.
In the majority of these studies, there were statistically significant differences in HRQOL between study arms. However, these differences were usually not present for all items and/or subscales on the instruments used and, in some studies (44, 50, 52) , differences in HRQOL on some scales were in opposite directions to those on other scales, making interpretation difficult. There was no consistent pattern to the domains influenced by treatment-i.e., pain, physical, psychological, social, interpersonal, and symptom scales or items all yielded statistically significant differences between study arms in at least one study. Furthermore, differences in HRQOL scores were sometimes seen at one time point in the trial and not at other time points (39, 49, 50) . Some studies that reported no statistically significant HRQOL effects were small [e.g., (43) ] or commented that statistical power was inadequate to detect a clinically important difference in HRQOL between study arms (47) . Low power, insensitivity of instruments (or specific domains) to change, or use of instruments that did not include domains likely †For "Missing data," "Statistical methods," and "Timing of HRQOL assessment," "Yes" means that the methodologic characteristic described in the text was satisfied; "No" means that the methodologic characteristic was not satisfied.
‡When only HRQOL outcomes (and not medical outcomes) were reported. "Yes" was entered. §Validated questionnaire.
Authors consider intervention beneficial even though all P>.05.
to be influenced by the interventions being studied may have contributed to some of the lack of statistically significant HRQOL differences between study arms in these studies. The goal of treatment in metastatic breast cancer has traditionally been palliation of symptoms, although the introduction of promising new agents in the last decade has led to studies in which survival benefits are sought. Disappointingly, HRQOL outcomes in these studies have provided little additional information beyond that obtained from traditional medical outcomes (including toxicity). In one study (34) , evidence of HRQOL benefits was present earlier than evidence of medical benefits; however, the identification of improvement in time to disease progression with continuous (as opposed to intermittent) chemotherapy was the key factor leading to selection of continuous treatment as the preferred approach. Another study (39) reported enhanced physical and psychological scores on the RSCL questionnaire for patients receiving anastrozole over patients receiving megestrol acetate in the absence of statistically significant effects on response rate, time to disease progression, or time to treatment failure. Some treatment toxicities were greater with anastrozole than with megestrol acetate treatment, and others, notably weight gain, were less. Given the equivalent medical outcomes of this study, the enhanced HRQOL in patients receiving anastrozole provides support for its selection as the preferred treatment; however, the association of anastrozole with reduced weight gain was probably sufficient to guide this selection. In a final study (36) , weekly doxorubicin was compared with doxorubicin administered every 3 weeks. No differences in medical outcomes or toxicity were identified; however, patients receiving 3-weekly therapy had better scores than those receiving weekly therapy on the psychological subscale of the RSCL at the midpoint of treatment but not at the end. Although the simpler logistics of 3-weekly administration of doxorubicin would probably be the most important determinant of treatment decisions in this situation, a transient psychological benefit provides additional support for such a decision.
Given the findings discussed above, the routine use of HRQOL measurement in randomized drug trials in metastatic breast cancer may not be warranted unless one or more of the agents being tested has very modest or differing toxicities that could have an effect on HRQOL. In none of the published studies reviewed here did HRQOL measurement provide information that had a clear effect on treatment recommendations. Careful measurement of toxicity and performance status, coupled with measures of tumor response and/or survival, usually provided sufficient information for treatment decisions. When treatments have equivalent tumor-related outcomes and competing toxicities are present or the logistics of treatment administration differ, as was the case in the two trials discussed above (36, 39) , then HRQOL measurement may help to shift the balance in favor of one treatment over another. However, HRQOL measurement could probably be deferred to a follow-up trial in the rare situations in which one of these scenarios occurs.
Symptom Control/Supportive Care and Follow-up
Eight randomized trials of symptom control/supportive care (54) (55) (56) (57) (58) (59) (60) and three trials of different approaches to investigation or follow-up of breast cancer patients (61) (62) (63) have included HRQOL outcomes (Table 6 ). HRQOL measurements were often performed in a subset of patients in these trials. Seven trials (54, 57, (59) (60) (61) (62) (63) provided information on overall rate of missing HRQOL questionnaires, but none reported the extent of missing items or the reasons for missing data. Two trials (55) provided no information on their statistical methods. Four of the symptom control trials (54-56) investigated chemotherapy-associated nausea using standard HRQOL instruments, including the RSCL, HADS, and FLIC. Ondansetron was shown to reduce emesis in three (54, 55) of these trials using emesis questionnaires or diaries. All three trials identified enhancement of at least one aspect of HRQOL by ondansetron. In a study by Razavi et al. (56) that evaluated alprazolam versus placebo to treat nausea and vomiting, no HRQOL effect was identified, although anticipatory nausea was improved. The use of bisphosphonates (e.g., pamidronate and clodronate) in breast cancer metastatic to bone was evaluated in three trials (57-59) using a variety of self-report HRQOL instruments [two additional studies (64, 65) were excluded from this review because they used the Spitzer QOL Index, which is observer, not patient, reported]. All of these trials of bisphosphonates identified important beneficial effects of using bisphosphonates on fracture rates, pain, hypercalcemia, and/or the use of radiation. One of the studies (57) , which used a novel HRQOL instrument that had been developed specifically for the trial, reported that HRQOL was better in patients treated with bisphosphonates than in patients treated with placebo. In a symptom control trial (60) , clonidine reduced hot flashes and improved HRQOL. Thus, when HRQOL outcomes were statistically significant, they were consistent with medical outcomes in these trials, and they also provided support for therapeutic decisions based on these medical outcomes. However, HRQOL outcomes were often not statistically significant in the presence of statistically significant medical outcomes.
The three follow-up trials (61-63) used a variety of questionnaires: EORTC QLQ-C30, MOS-SF-36, HADS, and POMS. In a trial comparing hospital-based with general practice-based follow-up (63) , change in the mean anxiety and depression score from baseline was transiently worse in the general practice group at midtrial compared with the hospital group; however, the magnitude of the change was small, and there were no statistically significant between-group differences. No other statistically significant medical, psychosocial, or HRQOL outcomes were reported in these trials.
Taken together, the results of these symptom control/ supportive care and follow-up studies suggest that measurement of HRQOL adds little if any benefit to traditional medical outcomes in these trials. The use of very focused measures of symptoms (e.g., pain, nausea), may have made general HRQOL measures redundant. However, it is disappointing to note that in two trials of bisphosphonates (58, 59) , HRQOL instruments failed to identify benefits of bisphosphonates that were readily apparent when traditional medical outcome measures were used. It might be argued that pain and nausea self-report measures are HRQOL measures; however, because they are unidimensional and do not measure function, we have not included them as traditional HRQOL measures. Unidimensional measures serve a purpose in studies of symptom control, however, and by focusing on those symptoms most likely to be influenced by treatment, they allow an evaluation of symptoms that is both more detailed and less burdensome than a general HRQOL measure would be. Thus, planners of symptom control studies might do well to select simple instruments that focus on the specific symptoms being studied rather than selecting general or even cancer-specific HRQOL instruments.
Given the absence of benefit with any outcome (i.e., medical or HRQOL) in the follow-up trials, it is difficult to draw conclusions about the potential contribution of HRQOL measurement in this setting. Low statistical power or a true lack of effectiveness of the interventions studied may have led to these negative results. Further research into a potential role for HRQOL measurements in trials using other (effective) interventions and/or larger sample sizes is clearly needed.
Psychosocial Interventions: Adjuvant, Metastatic, Symptom Control
The psychosocial intervention studies (Table 7) were conducted in the adjuvant, metastatic, and symptom control settings. Eleven trials (67) (68) (69) (70) (71) (72) (73) (74) (76) (77) (78) in the adjuvant setting involved breast cancer patients, one trial (75) involved partners of breast cancer patients, and one trial (66) involved breast cancer patients and their spouses. The interventions ranged from support groups (67, 70, 76, 77) , to individual or couple counseling (66, 69, 71) , to relaxation training (67, 70, 78) , to telephone counseling or screening (68, 73) . The most commonly used HRQOL instruments included the POMS, which was used in six studies, and multidimensional HRQOL instruments (i.e., FACT-B, FLIC, RSCL, and CARES), which were also used in six studies; other instruments included unidimensional measures drawn from the field of psychiatry (e.g., HADS and STAI). HRQOL measurements were available for all patients in most of the studies. The rate of missing HRQOL questionnaires was addressed to differing extents in all of these studies, but none reported missing items. Most studies provided information on statistical methods of analysis and on timing of HRQOL measurement. Only two of the adjuvant studies reported medical outcomes-immune parameters in one (70) and clinical or pathologic response to neoadjuvant therapy in the other (78) . Neither medical outcome was influenced by the psychosocial intervention.
Psychosocial benefits were identified in 10 adjuvant studies (67, (69) (70) (71) (72) (73) (74) (76) (77) (78) (Table 7) . Relaxation plus imagery improved mood (POMS) compared with relaxation alone or a control condition (67), whereas individual cognitive psychotherapy with family counseling improved depression and HRQOL (69) . A 6-(70) or 8-week (77) support or educational group enhanced overall coping skills (70), social functioning, and mental health (77) , whereas relaxation training plus imagery resulted in greater emotional control, improved mood, and relaxation (78) compared with a control group. Two nursing interventions reduced uncertainty (72) or stress reactions (71) , and individuals who watched an enhanced compassion videotape experienced less anxiety than those who watched a standard videotape (74) . Finally, women participating in a 6-week structured group intervention experienced improved mood and had increased vigor and enhanced use of a fighting spirit coping style (76) .
Interest in psychosocial interventions in metastatic breast cancer was stimulated by an early report that supportiveexpressive group therapy improved mood, reduced suffering from pain, and improved survival (79, 80, 87) . Five subsequent trials in this setting were identified (81) (82) (83) (84) (85) . All of these trials used the POMS and other psychological questionnaires; two also used more general HRQOL measures (82, 85) . The three trials that examined survival (82, 83, 85) failed to identify statistically significant effects of the intervention. Survival results are not yet mature in a fourth trial (84) . One trial (83) evaluated a 6-week cognitive-behavioral group intervention that identified beneficial effects on mood and self-esteem at its conclusion, but these benefits did not persist 3 or 6 months later. Another trial (85) reported enhanced mood and reduced pain but no change in HRQOL in women participating in long-term supportiveexpressive group therapy. Symptoms of post-traumatic stress disorder were reduced in women receiving supportiveexpressive group therapy (84) , and perceived ability to reduce pain was enhanced through the use of a relaxation-visualization intervention (81) .
The only psychosocial intervention trial focusing on symptom control (86) studied the use of a comprehensive menopausal assessment (symptom assessment, education, counseling and, as appropriate, specific pharmacologic and behavioral intervention) in healthy breast cancer survivors. Beneficial effects of the assessment, including the pharmacologic and behavioral interventions, were identified using subscales of both the CARES and the MOS-SF-36 instruments, consistent with improved menopausal symptoms identified using the Menopausal Symptom Scale.
Improvement in at least one psychosocial or HRQOL outcome was identified in the majority of the psychosocial intervention studies. In general, psychosocial interventions resulted in enhanced psychosocial functioning. Improvements in HRQOL were often identified with one psychosocial instrument but not with others, or in one subscale of an instrument but not in others, making interpretation of results difficult. In addition, these studies were less likely than studies of biomedical interventions to include multidimensional HRQOL measures; among the eight studies that did (69, 70, 72, 73, 78, 82, 85, 86) , statistically significant effects were identified in only two trials (77, 86) . Thus, it is important to tailor the selection of HRQOL and psychosocial instruments to the specific intervention being evaluated to ensure that outcomes (i.e., both psychosocial and HRQOL) likely to be influenced by the intervention are captured and to not rely solely on general or cancer-specific HRQOL instruments to identify treatment effects.
Although there has been considerable interest in the effect of psychosocial interventions on survival in breast cancer, a statistically significant effect was seen only in the original study of Spiegel et al. (87) . It is probably more reasonable to expect that psychosocial interventions would have an impact on psychosocial functioning and/or HRQOL outcomes. As a result, it would be anticipated that HRQOL outcomes would play an important role in guiding treatment recommendations in studies of psychosocial interventions. As can be seen in Table 7 , HRQOL outcomes did influence clinical decision making in all but one (79, 80, 87) of the psychosocial intervention trials reviewed here.
DISCUSSION
This review has identified several areas of inquiry where adding an assessment of HRQOL to randomized clinical trials in breast cancer contributes little to clinical decision making about treatment alternatives. This conclusion is particularly true when biomedical interventions are being evaluated. This result may reflect the lack of precision of the currently available HRQOL instruments (i.e., the dimensions measured are scaled too coarsely to detect changes or differences that matter to patients), the failure of existing instruments to capture important domains (e.g., cognitive functioning), or the ability of simpler measure-ments (e.g., toxicity) to provide similar information. However, it may also be that HRQOL outcomes are of secondary importance when medical outcomes, particularly survival, are statistically significantly affected by treatment. It is clear that when a treatment is medically superior to another, most patients will desire that treatment, even if there may be an increase in short-term toxicity (88) . Conversely, if treatments have equivalent medical outcomes, then differences in toxicity and HRQOL may be important. Perhaps HRQOL measures should be included in randomized biomedical treatment trials only when equivalency of treatments is likely and when differences in HRQOL will, therefore, become the primary factor influencing treatment decisions.
Other issues that are of increasing interest, given the growing number of long-term breast cancer survivors, are the long-term, late effects associated with adjuvant therapy. These long-term effects are particularly relevant to patients with small tumors who receive increasingly complex and intensive therapy and whose likelihood of long-term survival is high (89, 90) . Studies of long-term, late HRQOL effects are often attached to large randomized adjuvant therapy trials in which specific treatments and doses can be evaluated for their late effects; however, the inclusion of HRQOL outcome measures should be undertaken with specific hypotheses in mind. Investigators may opt instead to perform observational studies. Regardless of the study design used, HRQOL instruments selected for outcome measurement should include domains that are likely to capture the symptoms being studied, and the timing of those measurements should correspond to the time frame in which effects are anticipated. On the basis of our review of the literature, there may be little role for routine HRQOL measurement in studies of drug therapy for metastatic disease, provided that comprehensive toxicity and symptom data are collected and that the drugs used have been sufficiently studied so that unexpected HRQOL effects are unlikely.
In contrast to the largely noncontributory effects of HRQOL outcomes on clinical decision making in trials involving biomedical interventions, trials of psychosocial interventions have often demonstrated measurable effects on HRQOL outcomes. These effects have most often been identified using detailed psychosocial questionnaires (e.g., POMS) rather than multidimensional HRQOL instruments (e.g., EORTC QLQ-C30 or FLIC). To the extent that specific dimensions of psychosocial functioning are targeted in these interventions, appropriate HRQOL or psychosocial instruments known to be responsive to change in those dimensions can be selected. Because the incorporation of such measures appears to be essential to identifying the beneficial effects of these interventions (or the lack thereof), psychosocial intervention trials will probably continue to use measures that are drawn from the field of psychology rather than from the HRQOL measurement arena. To some extent, psychosocial intervention trials have had more funding, staff, and expertise to collect HRQOL and psychosocial outcome data from individual patients than biomedical intervention trials, making detailed evaluation of psychosocial outcomes more feasible. In contrast, most HRQOL measurements in biomedical intervention trials have had limited funding, are time constrained because of the challenges of adding these measurements to clinical treatment and, therefore, have often used short assessment batteries (see Tables 3-6 ). Whether the HRQOL outcomes in biomedical intervention trials would have been more compelling with more detailed HRQOL measurements is an open question that is worthy of investigation.
In making decisions about the inclusion of HRQOL end points in clinical trials, increased trial complexity, respondent burden, and cost should be balanced against the expected gain in knowledge, particularly when toxicity and targeted symptom data are also being collected, so that resources for HRQOL measurement can be allocated to those trials in which benefits are likely to be greatest (91, 92) . Our review provides little support for the routine incorporation of HRQOL measurements in all clinical trials in breast cancer when such measurement is intended to contribute to selection of optimal treatments. Although it is tempting to use other purposes of HRQOL measurement (e.g., description of patient experience and prognostic effects) as a justification for inclusion of these measurements in all randomized trials in breast cancer, the increased burden must be balanced against the likelihood that this information could be obtained using less expensive and time-consuming observational designs.
In terms of future research, there is a need for the development of targeted HRQOL instruments that contain items or scales that measure areas likely to be affected by breast cancer or its treatment that are not captured by general or even cancerspecific measures of HRQOL. Such items or scales include menopausal symptoms and cognitive functioning in trials of adjuvant therapy, and body-image symptoms (including arm symptoms related to surgery and radiation therapy) of long-term survivors in trials of primary therapy. This need could be addressed by the development of specific modules (an approach taken in the development of both the FACT and EORTC QLQ), by the addition of a small number of items (with appropriate validation) to existing questionnaires, or by the development of new questionnaires. It is noteworthy that treatment effects on social functioning were rarely identified in clinical trials using available HRQOL instruments. This lack of treatment effect may be because the treatments studied did not affect this domain; it may also be because this domain is poorly measured using available instruments. Existing instruments and any new instruments that are developed should be shown to be sensitive to clinically important changes in the domains they measure if they are to be used in clinical trials. This approach requires agreement by the research community, clinicians, and patients on what a clinically important change is (an area of active research) (93) and what scaling is sufficiently fine to detect those changes. It is also essential that sample size be calculated for HRQOL outcomes and not just for medical outcomes; these calculations should incorporate anticipated differences and variability in HRQOL outcomes.
Several general methodological and/or statistical issues that arise from the incorporation of HRQOL measurement into research of any type also need to be addressed. Examples of these issues include HRQOL instrument selection (which one? how many?); timing of HRQOL measurements (how often? over what period of time?); reconciliation of multiple HRQOL outcomes (i.e., convergence and divergence of results obtained from different HRQOL instruments or subscales at the same or different times); statistical analysis (multiple testing, use of summary statistics and measures, handling of missing data, and sample size calculations); and interpretation of results (medical outcomes versus HRQOL outcomes, hierarchy of HRQOL outcomes [e.g., are some symptoms or domains more important than others in making treatment selections?], clinically meaningful differences). Much of this fundamental research is underway, and it should be undertaken alongside work on the development and validation of specific instruments.
Where do we go from here? It would probably be wise to wait for the maturation of a number of clinical treatment trials that include many of the high-quality HRQOL instruments that are currently available. Once these trials report their treatment and HRQOL results, we can probably come to firm conclusions about the added benefit of the inclusion of HRQOL assessments in treatment trials in breast cancer. Our findings in this review, however, suggest a need for caution in initiating new HRQOL studies in breast cancer using existing general or cancer-specific HRQOL instruments unless treatment equivalency is an expectation (especially in the adjuvant setting) or unless the qualityof-life question targets unique or specific questions that can only be assessed through patient self-report.
